Neumega Related Published Studies
Well-designed clinical trials possibly related to Neumega (Oprelvekin)
[Effect of recombinant human interleukin 11 on recovery of platelets after peripheral blood hematopoietic stem cell transplantation]. [2009.02]
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. [2006.04]
[A clinical study of YM 294 (rhlL-11) in patients with gynecologic cancer] [2005.04]
Recombinant human interleukin 11 and bacterial infection in patients with [correction of] haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. [2003.01.25]
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. [2001]
Tolerability and side-effect profile of rhIL-11. [2000.09]
Clinical efficacy of rhIL-11. [2000.09]
Mechanism and amelioration of recombinant human interleukin-11 (rhIL-11)-induced anemia in healthy subjects. [2000.08]
Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. [1997.11]
Other research related to Neumega (Oprelvekin)
Oprelvekin-associated bilateral optic disk edema. [2005.02]
A multiple-dose, safety, tolerability, pharmacokinetics and pharmacodynamic study of oral recombinant human interleukin-11 (oprelvekin). [2004.10]
Periostitis secondary to interleukin-11 (Oprelvekin, Neumega). Treatment for thrombocytopenia in pediatric patients. [2003.07]
Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. [2003.06.15]
Oprelvekin. Genetics Institute. [2001.10]
Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia. [1999.09]
FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. [1998]
Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. [1996.09]
A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. [1996.05.01]
The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor). [1996]
Other possibly related research studies
A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. [2004.12]
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. [2004.05]
Treatment of drug-induced thrombocytopenia. [2002.07]
Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. [2003.05]
Pharmacogenomic analysis of rhIL-11 treatment in the HLA-B27 rat model of inflammatory bowel disease. [2002]
Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. [2001]
Protective effect of rhIL-11 in a murine model of acetaminophen-induced hepatotoxicity. [2001.03]
A pilot study of rhuIL-11 treatment of refractory ITP. [2001.03]
Subcutaneous or oral administration of rhIL-11 modulated the contact hypersensitivity response. [2000.12]
Dose reductions and delays: limitations of myelosuppressive chemotherapy. [2000.09]
Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. [2000.03]
Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals. [1998.10]
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. [2004.06]
Interleukin-11 administration normalizes the platelet count in a hypersplenic cirrhotic patient. [2002.10]
Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine. [1999.04]
Incorporating new modalities into practice guidelines: platelet growth factors. [1998.11]
Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. [2006.10]
Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. [2011.10]
|
